Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Venetoclax in Early Chronic Phase CML
NCT02689440Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2016
- Primary completion
- Dec 2040
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, venetoclax in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2016; status: active, not recruiting.
02
Drugs
dasatinibvenetoclax
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02689440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689440.